Engineering synthetic RNA devices for cell control

Peter B. Dykstra¹, Matias Kaplan¹ and Christina D. Smolke^{1,2}

Abstract | The versatility of RNA in sensing and interacting with small molecules, proteins and other nucleic acids while encoding genetic instructions for protein translation makes it a powerful substrate for engineering biological systems. RNA devices integrate cellular information sensing, processing and actuation of specific signals into defined functions and have yielded programmable biological systems and novel therapeutics of increasing sophistication. However, challenges centred on expanding the range of analytes that can be sensed and adding new mechanisms of action have hindered the full realization of the field's promise. Here, we describe recent advances that address these limitations and point to a significant maturation of synthetic RNA-based devices.

Sensor

An element that can detect signals, including nucleic acid sequences, proteins, small molecules or non-biological stimuli such as temperature and light.

Actuator

An element that can control a process or event.

Gene-regulatory RNA elements

RNA elements that control expression of a gene.

RNA devices

Engineered genetically encoded RNA elements that combine sensing and actuation activities.

Riboswitches

Natural RNA elements that conditionally regulate gene expression in response to binding of a small molecule.

RNA is more than a messenger. Genetics research has not only cemented the principles of gene expression control — that RNA molecules transmit genetic information between DNA and protein — but also uncovered the significant role that RNA plays in directly regulating cell behaviour (FIG. 1a). Because of its structural flexibility and ability to sense and interact with a range of inputs, RNA has proven to be an important tool in engineering research and sits on the precipice of widespread application on a par with that of proteins and DNA.

Synthetic biologists take inspiration from diverse fields of engineering to develop frameworks for the design, construction and characterization of new biological systems^{1–4}. A core concept is the engineering of systems that can receive an input signal (via a sensor), perform an operation and generate an interpretable output (via an actuator)⁵. Endeavours to engineer RNA benefit from customizable ligand-sensing and gene-regulatory RNA elements and tunable response characteristics. The advantageous qualities of RNA have led to the development of diverse synthetic RNA devices that sense, process and act upon genetic and molecular information⁶ (FIG. 1b).

Early RNA gene control elements were developed shortly after the discovery of functional riboswitches in nature^{7–9}. Owing to the central role of RNA in gene expression, many of these initial engineered systems focused on regulating translation to affect protein levels^{7,8,10}. Further advances generated RNA devices that integrated sensing and control activities and enabled more precise modulation of cellular functions¹¹. But whereas the RNA engineering field matured, several limitations persisted. One long-standing challenge in RNA device engineering is the limited set of analytes that can be sensed by RNA aptamers due to limitations in our

ability to predict or select for sequences that can bind and report binding. Having diverse options for selecting an input ligand tailored to a given system is important to advance applications and RNA engineering approaches have not yet scaled sensor development. However, recent developments in high-throughput strategies for generating RNA components that sense new analytes may rapidly change the landscape¹².

Another major challenge has been the limited mechanisms of action by which synthetic RNA devices can meaningfully affect cell function. Early RNA devices that focused on the modulation of mRNA levels and translational efficiency within cells¹⁰ tapped into a small subset of the wider possibilities for RNA modulation. Recently, novel design techniques around protein translation have demonstrated strategies that can achieve increased dynamic range and temporal control^{13–16}. Furthermore, approaches such as the use of synthetic components to harness natural processes and the de novo utilization of RNA for novel and artificial cellular functions showcase advanced mechanisms that open new avenues for the future of RNA engineering^{14,17}.

In this Review, we discuss current applications of RNA devices spanning research, biomanufacturing and clinical uses. We then review advances in expanding analyte sensing and mechanisms of action with engineered RNA. Recent reviews have comprehensively covered the topics of aptamer selection via systematic evolution of ligands by exponential enrichment (SELEX)¹⁸ and mammalian post-transcriptional circuits¹⁹. Here, we examine novel strategies to create new ligand sensors and engineered RNAs that regulate diverse cellular processes. We conclude with a perspective on the maturation of the RNA device field and areas where we anticipate new technologies will drive further key advances.

¹Department of Bioengineering, Stanford University, Stanford, CA, USA.

²Chan Zuckerberg Biohub, San Francisco, CA, USA.

✉e-mail: csmolke@stanford.edu

<https://doi.org/10.1038/s41576-021-00436-7>

Aptamers

Nucleic acid sequences that can bind a particular ligand, such as a small molecule or protein.

Components of synthetic RNA devices

A major research focus in synthetic biology is the development of modular frameworks for constructing genetically encoded devices and engineered biological systems

supported by the generation of well-characterized, biological component parts²⁰. RNA devices are engineered RNA sequences that combine distinct sensor and actuator components to encode higher-order function than

◀ Fig. 1 | **RNA cellular functions.** **a** | Following transcription, mRNAs are spliced by the spliceosome, a complex of small nuclear RNAs (snRNA) and proteins, and matured by the addition of markers such as a 5' cap (green circle) and polyA tail (green line)^{147,148}. Outside the nucleus, the canonical function of RNA is the combination of tRNAs, ribosomal RNAs (rRNAs) (with accompanying ribosomal proteins, making up the ribosome) and mRNAs to form translational complexes that produce most cellular proteins. Circular RNAs (circRNAs) are RNA molecules that form naturally via lariat intermediates as a splicing by-product¹⁴⁹. RNA regulation of cellular processes can be accomplished by circRNAs, as well as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) that can regulate levels of exogenous RNA, endogenous RNA and protein expression^{150,151}. **b** | RNA device engineering. Parts for RNA devices can be obtained by mining natural sequences, selection experiments or rational design of sequences. Sensing and actuating components can be characterized and combined to form an RNA device with both sensing and actuation capabilities.

the components by themselves (FIG. 1b). In general, the sensor and actuator components are physically coupled such that binding of a ligand to the sensor component alters the activity of the actuator component⁵. The quantitative activity of the actuator component is therefore a read-out of the bound state of the sensor component and, ultimately, the concentration of the target ligand in the cellular environment.

RNA sensors can detect a range of biological inputs including nucleic acids, proteins and small molecules (FIG. 1b). RNA aptamers are a class of RNA sensors that bind molecular ligands via direct binding interactions. The quantitative activity of an RNA device is highly dependent on aptamer affinity and specificity. The ligand concentration range that a device is capable of reporting, its sensitivity (this is often reported as the EC₅₀, the half maximal effective concentration), is closely coupled to the affinity of the incorporated aptamer. Cells contain many structurally similar molecules and aptamer specificity is critical to ensuring that the device reports on the desired molecular target. Starting from the analyte-sensing RNA sequences found in natural systems, researchers have worked to expand the number and diversity of molecular ligands that can be detected by RNA. Efforts have been split between mining genomes for new aptamers²¹ and generating de novo aptamers through high-throughput selection^{22,23}. Both of these methods have faced limitations in generating new RNA aptamers, with RNA aptamers against approximately 100 small molecules and 400 proteins currently reported^{24–27}.

RNA actuators are typically encoded by gene-regulatory or enzymatic components that control a process or event (FIG. 1b). In early examples, RNA devices inspired by natural riboswitches were used to control translation of gene expression in bacteria¹⁰. These RNA devices were located within the 5' untranslated region of a target mRNA and modulated translation initiation of the encoded gene sequence by controlling ribosome binding site accessibility via alteration of RNA structure in that region¹⁰. Other early RNA devices modulated translation levels by controlling the degradation rate of the target mRNA with a self-cleaving ribozyme switch²⁸. Additional designs have incorporated actuators that work through RNA interference-mediated silencing²⁹, antisense-mediated silencing³⁰ or transcription termination³⁰. The majority of RNA devices described to date utilize actuators that control gene expression, and more generally have faced limitations in gene-regulatory dynamic range and ligand

sensitivity^{31–34}. Over the past decade, roles for RNA beyond control of translation through the central dogma have been better understood — including microRNAs (miRNAs), circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), spliceosome processing and CRISPR biology — providing opportunities to expand the mechanisms and systems through which RNA devices can act.

Emerging applications of RNA devices

RNA devices enable advances in basic research. RNA devices have been applied as tools to address specific bottlenecks and propel basic research forward. One such bottleneck is the need to determine the cell state by detecting endogenous protein expression. Techniques to monitor protein levels such as western blotting, immunostaining and liquid chromatography–mass spectrometry face difficulties in detecting proteins in living cells. RNA devices offer a promising solution by combining a protein-responsive RNA aptamer with a simple fluorescent read-out. One example of this approach is an mRNA device design that can distinguish between undifferentiated human induced pluripotent stem cells and differentiated cells by quantifying endogenous LIN28A protein levels³⁵ (FIG. 2Aa). This categorization method based on detecting key endogenous protein levels could pave the way for future strategies in live-cell detection or purification of specific cell types for regenerative medicine.

RNA devices can also be used to study RNA folding inside living cells. Current techniques for studying in vivo RNA folding are lacking, but advances in the engineering of fluorescent RNA aptamers could potentially fill this need. Certain RNA aptamers can combine with specific small molecules to create a fluorescent complex. Researchers have improved upon early demonstrations in this space³⁶, creating an RNA aptamer-based Förster resonance energy transfer (FRET) system by placing fluorescent aptamers on RNA scaffolds³⁷ (FIG. 2Ab). This apta-FRET system reports on RNA conformational changes and offers a general tool for studying the folding and conformational changes of natural and artificial RNA structures in vivo.

RNA devices also provide new ways to improve disease models. For instance, *Caenorhabditis elegans* can be used to study diseases such as Huntington's disease, but suffers as a model system from a dearth of convenient methods for achieving conditional gene expression induction. Recent work described a tetracycline-dependent ribozyme switch that can confer inducible control when inserted into the 3' untranslated region³⁸ (FIG. 2Ac). This system was used to establish an inducible *C. elegans* polyglutamine Huntington's disease model that exhibited ligand-controlled polyQ-huntingtin expression, inclusion body formation and toxicity. Although this inducible gene expression platform provides notable advantages over attempts to combine multiple components into the host genome, the dynamic range of the gene induction was limited compared with other methods used in *C. elegans*. Future efforts may leverage reported screening strategies to optimize switch activity that increase the dynamic range in a desired model system.

Ribozyme switch

A type of riboswitch that uses a ribozyme, an RNA element that acts through cleaving RNA, to encode the actuation component.

A Basic research

a Distinguish cell type by endogenous protein detection

b Aptamer-based FRET system

c Disease modelling in model organisms

B Biomanufacturing

a High-throughput monitoring of intracellular concentrations

b Dynamic control of metabolic flux

C Human health

a Regulation of T cell proliferation

b Gene editing control and transcriptional regulation

c Inducible control of gene therapy

Fig. 2 | RNA devices enable diverse applications. Versatility of RNA devices highlighted in the wide application space of RNA devices ranging from addressing bottlenecks in basic research (part **A**), to providing advancements in biomanufacturing (part **B**) to propelling new frontiers in human health (part **C**). **Aa** | Detecting and quantifying endogenous LIN28A protein levels enables qualitative distinction between undifferentiated human induced pluripotent stem cells and differentiated cells³⁵. **Ab** | RNA aptamers can be combined to create an aptamer-based Förster resonance energy transfer (FRET) system for studying RNA folding inside living cells³⁷. **Ac** | A tetracycline-dependent ribozyme switch controls polyQ-huntingtin expression and inclusion body formation in a novel inducible *Caenorhabditis elegans* polyglutamine Huntington's disease model³⁸. **Ba** | Cytoplasmic

small-molecule concentrations can be monitored with ribozyme switches engineered to respond to specific metabolites³⁹. **Bb** | Metabolite-responsive ribozyme switches integrated into cellular pathways enable reprogramming of networks for dynamic control of metabolic flux⁴⁰. **Ca** | Insertion of a 6R-folinic acid (6R-FA)-responsive aptamer into microRNA (miRNA) switches enables regulation of T cell proliferation through control of miRNA processing⁴⁴. **Cb** | CRISPR guide RNA (gRNA) engineered with RNA aptamers that use a strand-displacement mechanism can lead to transcriptional regulation by 'dead' CRISPR-Cas9 (dCas9) (REF.⁴⁵). **Cc** | A ribozyme switch can enable inducible control of anti-vascular endothelial growth factor (anti-VEGF) proteins in a mouse model of wet age-related macular degeneration (AMD)⁵⁶. GlcNAc, N-acetylglucosamine.

RNA devices detect and enhance metabolite production. The ability to sense and monitor intracellular concentrations of metabolites is important for using biological systems to produce valuable small molecules at scale. Although existing technologies such as high-performance liquid chromatography, liquid chromatography–mass spectrometry and others can be used to quantify concentrations of metabolites in biological samples, such analytical assays are of low throughput and only provide bulk assay measurements. An RNA device responsive to a specific metabolite offers a high-throughput, real-time and, potentially, single-cell alternative to current methods. In one example, *in vitro* selection was used to generate a series of engineered ribozyme switches that sense and respond to cyclic diguanosyl-5'-monophosphate (c-di-GMP)³⁹ (FIG. 2Ba). The ribozyme switches were constructed by joining a self-cleaving hammerhead ribozyme (HHRz) to an aptamer from a natural c-di-GMP riboswitch. These detectors quantitatively estimated cytoplasmic concentrations of c-di-GMP as low as 90 nM by assaying *Escherichia coli* lysate, thus demonstrating their use as convenient tools to monitor metabolite levels.

More recent work also showcases strategies that incorporate metabolite-responsive ribozyme switches into cellular systems for dynamic control of metabolic flux. In an effort to overproduce *N*-acetylglucosamine (GlcNAc), metabolic networks in *Bacillus subtilis* were reprogrammed using a glucosamine-6-phosphate (GlcN6P)-responsive *glmS* ribozyme switch⁴⁰ (FIG. 2Bb). By linking the GlcN6P-responsive ribozyme switches to the regulation of multiple target proteins involved in the peptidoglycan synthesis, glycolysis and GlcNAc synthesis pathways, researchers demonstrated an engineered cell system that doubled the total GlcNAc titre. GlcN6P is an essential metabolite with variable concentrations and although the system worked well at fairly high GlcN6P concentrations, the limited dynamic range of the *glmS* ribozyme switch meant that optimal GlcNAc synthesis was difficult to achieve at low GlcN6P levels. However, because the intermediate GlcN6P is involved in the biosynthesis of numerous products in addition to GlcNAc, with further optimization of the *glmS* ribozyme switch, this dynamic control strategy can enhance engineering of additional metabolic pathways for small-molecule production in *B. subtilis* and other industrial microbes.

Human health as the next frontier of RNA engineering.

Advances in RNA device engineering have propelled applications in human health. The incorporation of RNA devices offers distinct advantages in human health applications by facilitating therapeutic applications owing to their ability to encode multiple activities (including sense and respond functions) into a small genetic footprint for cellular delivery. The human immune response is a key area of interest for applying engineering biological tools to medicine. T cell immunotherapies, such as chimeric antigen receptor T cell (CAR-T cell) therapies, seek to reprogramme patients' immune cells to find and attack cancer cells. However, a primary issue with using CAR-T cells is the lack of ability to control cell behaviour and function *in vivo* after cell delivery. CAR-T cells

can show powerful efficacy, but CAR-T cell-associated toxicities such as abnormally high cytokine production and massive *in vivo* T cell expansion have presented a major obstacle⁴¹. In response, the field has sought different ways to tailor individual treatments and develop safeguards against CAR-T cell-associated toxicities, including suicide switches to control cell death⁴². One early foray into genetic control of T cell proliferation used ribozyme switches to modulate expression levels of multiple cytokines, directing cells to either proliferate or undergo apoptosis⁴³. Theophylline-mediated regulation of clonal T cell growth was demonstrated over 2 weeks *in vivo* along with effective control over primary human T cell proliferation. More recent work focused on the regulation of endogenous cytokine receptor subunits and developed synthetic miRNA-based RNA devices responsive to the biologically inert drug leucovorin ((6R)-folinic acid (6R-FA))⁴⁴ (FIG. 2Ca). Combinatorial targeting of multiple receptor subunits with the incorporation of multiple miRNA switches responsive to (6R)-FA resulted in dynamic regulation of T cell growth, with up to 4-fold higher growth after addition of (6R)-FA and up to 26-fold diminished growth after removal of (6R)-FA. Taken together, these approaches offer a versatile strategy to address CAR-T cell-associated toxicities.

Applications requiring direct editing of the genome with CRISPR–Cas can also benefit from RNA devices. Leveraging the dependence of the CRISPR system on a guide RNA (gRNA), researchers designed a control system that incorporates small molecule-responsive aptamers into the 3' region of the gRNA to modulate its structure⁴⁵ (FIG. 2Cb). Initially, the spacer (which is complementary to the target sequence) is occluded. Ligand binding exposes the spacer sequence. The exposed sequence allows a catalytically inert 'dead' CRISPR–Cas9 (dCas9) to bind to the target sequence and silence the gene. More recent work demonstrated similar small molecule-responsive control of CRISPR interference (CRISPRi) activity by incorporating similar RNA devices into CRISPR–Cpf1, showcasing the versatility of this strategy⁴⁶. A separate example incorporated small molecule-responsive ribozyme switches into the 5' region of the gRNA. Here, the spacer is occluded by a complementary strand. In contrast to the above structural rearrangement mechanism, the spacer is exposed, and the complex activated, when the complementary strand is cleaved by the *cis*-acting ribozyme in the presence of a ligand⁴⁷.

Small molecule-responsive RNA controllers still face challenges related to the specificity and affinity of the incorporated aptamers. A more clinically advanced method for cell-specific control of translation via genome editing with a CRISPR effector has been demonstrated through the use of miRNA-controlled translation^{48–50}. This system combined a CRISPR effector and an anti-CRISPR gene with miRNA response elements (MRE) in the 3' untranslated region. The described system leveraged tissue-specific expression of miRNAs to direct repression of the anti-CRISPR proteins through the MREs and, thus, enable tissue-specific inhibition or activation of the CRISPR effector. The system was demonstrated in an *in vivo* mouse model, where

MREs complementary to miR-122 (a liver-specific miRNA) directed gene editing to occur only in the liver, even with the RNA device delivered to all tissues via an adeno-associated viral (AAV) vector⁵¹. These advances in incorporating RNA devices into CRISPR systems offer new strategies for temporal and conditional control of genome editing and transcriptional regulation that could lead to reductions in off-target effects⁵².

Clinical gene therapy is another health application space where the incorporation of RNA devices may improve clinical outcomes and safety. A primary method of gene therapy uses AAV vectors to deliver therapeutic genes to the patient. The small genetic size of RNA devices offers particular benefits for AAV vectors, which suffer from size constraints, only packaging ~4.7 kb⁵³. Engineered ligand-responsive and miRNA-responsive RNA devices provide a compact control system, requiring just ~100 bp of plasmid space⁵⁴. In one example, a guanine-responsive ribozyme switch was used to suppress transgene expression during AAV production and increase subsequent AAV vector yield up to 23-fold after addition of guanine⁵⁴. Later work demonstrated the portability of the RNA device strategy by inserting the same guanine-responsive ribozyme switch to repress transgene expression from a replication-incompetent vesicular stomatitis virus (VSV) vector by more than 26-fold in mammalian cells⁵⁵. The use of small molecule-responsive RNA devices has also been demonstrated in a mouse model of wet age-related macular degeneration (AMD)⁵⁶ (FIG. 2Cc). Current treatments for wet AMD use repeated large-bolus injections of anti-vascular endothelial growth factor (anti-VEGF) agents into the eye. Repetitive bolus dosing is associated with accelerated retinal degeneration, and there is a clear need to develop a long-term, single-use treatment for wet AMD that allows for tight temporal control of anti-VEGF agent expression. In this application, a tetracycline-responsive ribozyme switch delivered via a recombinant AAV vector enabled small molecule-controlled overexpression of an anti-VEGF protein and led to near complete inhibition of wet AMD disease lesions in mice⁵⁶. More recent work showcased a tetracycline-responsive ribozyme switch also able to effectively control AAV-mediated transgene expression that demonstrated 15-fold induction, reversibility and multiorgan functionality — key clinical features that highlight the applicability of RNA devices for gene therapy⁵⁷.

Finally, RNA devices have been applied to targeted cancer therapies using multiple methodologies that may overcome the clinical barriers of high cost, laborious techniques or safety concerns common to other treatments. One recently described approach takes advantage of a *trans*-splicing ribozyme to selectively inhibit hepatocellular carcinoma up to 86% through specific replacement of telomerase reverse transcriptase (TERT) RNA in human TERT (hTERT)-positive liver cancers⁵⁸. Adenovirus was used to deliver a *trans*-splicing ribozyme under the control of miR-122, a miRNA that is highly expressed in the liver, that specifically targeted, cleaved and then ligated the hTERT mRNA introducing a therapeutic gene RNA modification. This approach demonstrated that a cancer-specific RNA

device could treat hepatocellular carcinoma by enabling a post-transcriptionally regulated RNA replacement strategy. In an alternative strategy, RNA aptamers were used to target and induce apoptosis in human NCI-H460 cells, a model of non-small cell lung cancer⁵⁹. The RNA aptamers were capable of inhibiting NCI-H460 cell viability in a dose-dependent manner, with half-maximal inhibitory concentration (IC₅₀) values in the 100 nM range. Although there is potential immunogenicity from the AAV vector⁶⁰, this method, once delivered, draws on the small size, specific binding and tissue-penetrative ability of RNA aptamer-based devices for targeted cancer therapy.

One concern for the use of RNA devices in human health applications is the natural immunogenicity of RNA⁶¹. The ubiquitous presence of RNA viruses has marked RNA and, especially, double-stranded RNA to be a particularly strong pathogen-associated molecular pattern (PAMP), leading to rapid immune responses in humans through pathways such as RIG-I^{62,63}. This immunogenicity has been shown to be reduced by replacement of uridines with N¹-methylpseudouridine, RNA circularization and RNA designs that lack double-stranded regions^{64–68}. Immunogenicity can be further mitigated by masking RNA PAMPs within lipid nanoparticles during delivery⁶⁹. These advances in addressing RNA immunogenicity offer various strategies to streamline the translation of RNA devices to the clinic.

Cellular information sensing

The ability to design cell-control devices requires scalable strategies for developing genetically encoded aptamers with affinities and specificities that enable recognition of diverse cellular signals in the complex background of the cell environment. Although advances have also been made in the development of RNA molecules for sensing nucleic acid sequences, proteins and even non-biological stimuli, such as temperature and light^{70–73}, we focus here on recent advances in strategies for the scalable generation of RNA aptamers for small-molecule sensing.

SELEX as a model for de novo generation of nucleic acid aptamers. High-throughput selection techniques such as SELEX have been successful in scaling the number of aptamers that sense proteins, but selection for aptamers against small-molecule ligands has had limited success⁷⁴. This discrepancy is largely due to the enrichment strategies used in conventional high-throughput selection approaches. A large nucleic acid library is mixed with the ligand(s) of interest, and the sequences that bind to the ligand are then separated from those that do not bind the ligand. Separation techniques generally utilize the size or mass difference between an aptamer and the aptamer–ligand complex to recover the ligand-binding sequences and favour methods that can be performed in high throughput (for example, membrane binding or capillary electrophoresis).

Although there is a large size difference between the aptamer and the aptamer–ligand complex when the ligand is a protein, this is not the case when the ligand is a small molecule. Methods developed to recover aptamer–small-molecule ligand complexes generally

covalently link the small molecule, through a linker, to purification modalities such as magnetic beads, resins or a glass surface. Conjugating the small-molecule ligand to such linkers results in several challenges, including a lower-throughput process and enrichment of aptamers that bind to the conjugated molecule rather than the unconjugated molecule. The purification tags are normally conjugated onto reactive elements in the target molecule, removing functional groups that can interact with the aptamer^{22,75}.

The critical properties of an RNA aptamer are its specificity (its ability to distinguish between molecules of similar structures) and affinity (how tightly it binds the ligand). High-specificity aptamers are often required for RNA devices used in cellular applications where many similarly structured molecules to the target ligand may be present. Such instances include discriminating between small molecules in a biosynthetic pathway or sensing specific molecules in a diagnostic setting. The required affinity of the aptamer incorporated in an RNA device will depend on the intended application and the anticipated concentration range of the ligand in the cell environment. Ultimately, the EC_{50} value of the RNA device, which is directly related to the affinity of the incorporated aptamer⁷⁶, should be within the biologically relevant range of the target ligand. Both specificity and affinity can be tailored during the selection process for an aptamer. For example, negative or counterselection steps (that is, selecting against ligands of similar structures) can be incorporated to tune the specificity of an aptamer⁷⁷. Similarly, affinity can be increased by lowering the ligand concentration as the selection progresses to place selective pressure for higher-affinity aptamers^{75,78,79}. Finally, once an aptamer is generated, further tuning of specificity and affinity is possible through directed mutagenesis or rational engineering^{80–83}. Despite advances in RNA aptamer selection and engineering, the total number of small molecules that can be sensed remains limited, and the imminent need for increased numbers of genetically encoded sensors requires an exponential expansion of our current throughput. Overcoming this barrier will require focused effort on improving enrichment efficiency of small-molecule aptamer selection, post-selection tuning of aptamer properties and computational modelling of RNA–ligand binding.

Capture-SELEX enhances selection for small-molecule ligands. One recently described method, Capture-SELEX, utilizes structural changes between the ligand bound and unbound states of an RNA aptamer to enable a more efficient selection strategy for non-modified small-molecule ligands^{23,84} (FIG. 3a). This method immobilizes biotinylated oligonucleotides, called capture oligos, onto a streptavidin-covered magnetic bead. An RNA library consisting of 10 randomized nucleotides and 40 randomized nucleotides on either side of a capture sequence complementary to the capture oligos is transcribed and allowed to bind to the capture oligos. Small molecules of interest are added to the mixture and a small subset of the RNAs will bind to the ligands, disturbing the RNA–DNA interaction and causing the ligand-binding

RNAs to be released from the beads. The released RNA is then recovered and separated from the remaining captured RNAs, reverse transcribed and sequenced, or put through further rounds of selection. After nine rounds of selection, Capture-SELEX generated RNA aptamers against adenosine triphosphate (ATP) in a mixture of multiple competing small molecules⁸⁵. However, new aptamers created with Capture-SELEX are developed outside a biosensor context and must be subsequently incorporated into an RNA device framework for use in cellular control, which may require further modification and testing. Improvements in the method would allow direct selection of aptamers in their final RNA device context and scale up the development of new aptamers.

DRIVER utilizes ribozyme cleavage to automate selection strategy. A second recently described method, DRIVER (de novo rapid in vitro evolution of RNA biosensors), relies on sequence changes between the ligand bound and unbound states of an aptamer-coupled ribozyme device to enable an entirely in-solution selection strategy that can be executed autonomously on a liquid handling robot⁸¹ (FIG. 3b). DRIVER utilizes a device framework that couples an aptamer to a ribozyme, in which binding of the ligand to the aptamer controls the ribozyme's self-cleavage activity. A library is created that contains two randomized regions, a shorter sequence of up to 8 random nucleotides and a longer sequence of up to 60 random nucleotides, on loops I and II of the HHRz. These libraries are transcribed in the presence or absence of a small-molecule ligand mixture. A given HHRz molecule will either remain intact or undergo self-cleavage depending on its folded structure and ligand-bound state. A novel splint oligonucleotide is used to specifically recover and amplify cleaved sequences from the reaction mixture, whereas a standard primer is used to recover uncleaved sequences. The reaction is then run over multiple cycles with or without ligand present. In the absence of ligand, only cleaved sequences are recovered and in the presence of ligand, only uncleaved sequences are recovered. The alternating cycles allow for selection of ligand-responsive ribozyme switches.

In the original demonstration of the DRIVER method, small molecule-responsive RNA biosensors with nanomolar and micromolar affinities were generated against six small molecules, five of which had no previously reported aptamers⁸¹. Aptamers created via DRIVER can be used in the HHRz framework directly as genetic controllers or can be isolated and used separately. However, isolation of functional switches via DRIVER can require more than 100 rounds of selection owing to low enrichment efficiencies caused by the persistence of sequences that naively fold into cleaving and non-cleaving conformations independent of ligand concentration⁸⁶. DRIVER makes such intensive selection viable by automating the process on a liquid handling robot system so that an entire selection experiment against multiple ligands in parallel can be performed in a high-throughput manner. Although DRIVER exhibits robust ability for novel sensor generation, some limitations require consideration in its broad application. Because bulk selection conditions in DRIVER are not

◀ **Fig. 3 | Novel methods accelerate RNA sensor selection.** Overview of two methods for selection of RNA aptamers or sensors. Both methods begin with a diverse DNA library consisting of 10^{12} – 10^{15} distinct members. **a** | In the Capture–SELEX (systematic evolution of ligands by exponential enrichment) method^{23,84,85}, initial sequences consist of a 5′ and 3′ constant region flanking two randomized regions of 10 or 40 nucleotides with a constant docking sequence in the centre. The transcribed library is then hybridized to a biotinylated oligonucleotide via base pairing of the docking sequence. The complexes are immobilized on streptavidin-coated magnetic beads and mixed with the target molecules. RNA sequences that bind the target molecules and undock from the biotinylated oligonucleotides are subsequently eluted from the beads, creating the starting library for the next selection cycle. **b** | In the DRIVER (de novo rapid in vitro evolution of RNA biosensors) method⁸¹, libraries are designed based on a modified hammerhead ribozyme (HHRz) from satellite RNA of tobacco ringspot virus (STRSV) — a small, naturally occurring self-cleaving ribozyme — with the two loops replaced by either a randomized 30–60mer or a randomized 4–8mer. Sequences are mixed with target molecules. Desired RNA biosensor sequences cleave in the absence of the target molecule but bind to the target molecule when present, preventing cleavage. In iterative cycles of negative and positive selection, the RNA sequences are reverse transcribed (txn) and the resultant cDNA of cleaved sequences has a 5′ primer ligated that allows for selective PCR amplification of the sequences corresponding to either the cleaved or uncleaved RNA. The amplified DNA library then serves as the starting library for a new round of DRIVER. Periodically, these libraries can be analysed following quantification by next-generation sequencing (NGS). Part **a** reprinted with permission from REF.⁸⁵, Elsevier.

optimized to generate switches responsive to specific ligands, some DRIVER-derived sensors may require further optimization post selection. The DRIVER method also only generated ribozyme switches responsive to a small subset of all tested ligands. It is unknown whether this is a limitation of the types of ligands that RNA can sense or a limitation of the pooled, multiplexed process in which the DRIVER selections were performed. Future work should focus on scaling the throughput of DRIVER and demonstrating the utility of DRIVER-selected switches in diverse applications.

Sequencing methods enable high-throughput optimization of existing aptamers. High-throughput methods have recently been described with streamlined workflows for generating RNA devices from existing aptamers. The aptamer sequences are generally integrated into an RNA device framework and then regions of the device are randomized. As the aptamer sequence already exists, the library sizes can be drastically reduced from those used in methods such as Capture–SELEX and DRIVER. The smaller starting library sizes allow researchers to collect activity data for all library members, as well as run selection and functional assays in the cell systems that the RNA devices will ultimately be used in^{87–91}. For example, fluorescence-activated cell sorting followed by sequencing (FACS–seq) and RNA-sequencing (RNA-seq) approaches were recently used to screen RNA device libraries based on existing small-molecule aptamers to identify sequences that result in gene expression control in human cells⁸⁷. As these approaches can suffer from time-intensive and cost-intensive steps, efforts have also focused on developing a high-throughput method for the identification of synthetic RNA devices based on existing aptamers by barcode-free amplicon sequencing⁸⁸. This method was applied to screening RNA device libraries based on existing tetracycline and guanine aptamers and leveraging ribozyme cleavage (that is, HHRz, hepatitis delta virus

and Twister ribozymes) and U1–snRNP polyadenylation mechanisms in human cells. Taken together, these methods also showcase the modularity possible with RNA parts — aptamers generated in one context can be incorporated across diverse device platforms.

RNA processing and cell control

RNA devices are integrated into cellular regulatory networks from which they can control and probe biological processes. Here, we highlight recent advances in engineered RNAs acting as actuators. These novel RNA regulatory strategies provide opportunities for researchers to expand the mechanisms through which RNA devices can act.

RNA base modifications enable tuning of translation.

One of the more nuanced forms of RNA regulation is based on post-transcriptional modification of bases in RNA⁹². Sequencing of tRNAs revealed the first discovered RNA modifications to be pseudouridine (ψ) and *N*-methylation of nucleotides that have been shown to increase processivity of the ribosome and lower the translational error frequency^{93,94}. Newer sequencing techniques, such as *N*⁶-methyladenosine (*m*⁶A) sequencing (*m*⁶A-seq)⁹⁵ and methylated RNA immunoprecipitation sequencing (MeRIP-seq)⁹⁶, have allowed the mapping of the role of RNA post-transcriptional modification in biological processes. Using these techniques, *m*⁶A has been revealed as vital to gene control and linked to cancer^{92,97}. *m*⁶A modifications affect mRNA stability and translation through a set of methyltransferases, demethylases and proteins that can read out *m*⁶A modifications — so-called writers, erasers and readers⁹⁸. RNA actuators have been constructed that can add and remove *m*⁶A modifications from a target RNA by fusing methyltransferases to a catalytically inactive CRISPR-associated nuclease Cas13 (REF.⁹⁹) (FIG. 4Aa). Leveraging Cas13, which can selectively target RNA complementary to its loaded gRNA, the fused methyltransferase catalyses the conversion of specific adenosines to *m*⁶A. This work showed that the translation of mRNAs with known *m*⁶A sensitivity could be tuned via these targeted modifications. Further studies are required to fully understand how *m*⁶A modifications affect RNA stability and translation in cells, and whether this approach can be expanded to the broader cellular suite of readers, writers and erasers. Additionally, future work can explore whether this type of artificial methylation can be used to programme other processes such as alternative splicing¹⁰⁰.

Advances in RNA-targeting proteins have led to a renaissance in RNA base editing for scientific and therapeutic uses^{101,102}. Although much of the attention of genome engineering is focused on editing DNA, RNA editing may allow for non-permanent gene therapy techniques and targeting of conditions that can only be altered post-transcriptionally. These actuation mechanisms function by linking an RNA-targeting complex, such as CRISPR–Cas13, CRISPR–Cas9 or endogenous human RNA-binding proteins to an enzyme capable of modifying an RNA base, such as adenosine deaminase acting on RNA (ADAR) domains^{103–105} (FIG. 4Ab).

A RNA post-transcriptional modifications

Aa Targeted RNA methylation

Ab Targeted RNA base editing

B CircRNA

Ba Extended protein production

Bb miRNA sequestration

C RNA scaffolds

Ca Control of metabolite production

Cb Control of apoptosis

Fig. 4 | Emerging mechanisms of RNA processing and cell control for novel RNA devices. Recent findings have revealed new roles and mechanisms for RNA beyond control of translation through the central dogma, including targeted RNA base editing and post-transcriptional modifications (part **A**), circular RNA (circRNA) mechanisms (part **B**) and novel uses of RNA scaffolds (part **C**). Future RNA devices can incorporate these new mechanisms. **Aa** | Post-transcriptional modifications are involved in RNA regulation. N⁶-Methyladenosine (m⁶A) is a post-transcriptional modification affecting mRNA stability and translation. Methyltransferases can be fused to dCas13 (a catalytically inactive CRISPR-associated nuclease) directed by a guide RNA to catalyse the conversion of adenosines to m⁶A, allowing targeted artificial methylation of RNA which could be further utilized⁹⁹. **Ab** | RNA base editors use naturally occurring and evolved

enzymes to modify RNA nucleobases for post-transcriptional gene editing. Current editors utilize deaminases to convert adenosine and cytosine to inosine and uracil, respectively^{103,104,106,152}. **Ba** | circRNA expression vectors express proteins for longer than equivalent mRNA sequences¹⁰⁷. **Bb** | Synthetic circRNAs can be designed as microRNA (miRNA) sponges to quench specific miRNAs and inhibit miRNA-dependent viral replication¹²⁰. **Ca** | RNA can be repurposed as a scaffold to co-localize enzymes and increase local enzyme concentrations for control of metabolite production¹²⁵. **Cb** | RNA scaffolds can also be constructed to induce proximity oligomerization of Caspase 8 within the caspase pathway for apoptosis¹²⁶. ADAR, adenosine deaminase acting on RNA. Part **Aa** is adapted from REF.⁹⁹, Springer Nature Limited. Part **Cb** is adapted from REF.¹²⁶, CC-BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>).

The RNA-targeting domain brings the deaminase enzyme in proximity with an adenosine, thus deaminating the adenosine into an inosine. Recent work has expanded the toolbox to allow for the editing of cytosines to uridines¹⁰⁶. Future work may focus on developing additional editing domains to allow for all RNA bases to be modified to every possible other base, as well as the incorporation of this regulatory mechanism into

RNA device frameworks for conditional control of editing functions.

Circular RNAs as temporally stable translation platforms and molecular sponges. Another area of RNA regulation where our understanding of the underlying biological processes has recently advanced is circRNA¹⁰⁷. circRNAs are RNA molecules that take the form of a covalently

closed loop due to post-transcriptional processing¹⁰⁸ (FIG. 1a) and have been shown to play a pathological role in numerous diseases, including cancer, Alzheimer disease and cardiovascular disease^{109–111}. There is also evidence that circRNAs can encode proteins and regulate translation by serving as sponges for miRNAs and RNA-binding proteins^{112–114}.

Methods for synthesizing engineered circRNA devices in cells have been described that use various mechanisms, including ribozyme cleavage and tRNA ligation, group I self-splicing introns and back-splicing^{115–117}. Each of these methods was demonstrated to create synthetic circRNAs that can be translated to proteins in cells. It was hypothesized that circRNAs can persist longer in cells than mRNAs as they lack ends accessible to exonuclease activity; this increased stability was demonstrated by showing that luciferase activities from a circRNA and an mRNA were comparable, whereas the circRNA exhibited a protein production half-life (that is, time for luciferase activity to decrease by 50%) of 80 h compared with 45 h for the comparable mRNA¹¹⁶ (FIG. 4Ba). The persistence of circRNAs has been leveraged as a platform for the expression of RNA devices. Ribozyme-assisted circular RNAs (racRNAs) are a class of RNA devices that can be expressed in cells at high concentrations, increasing device concentrations from the low nanomolar to micromolar range¹¹⁵. The platform places the RNA sequence of interest between two ribozymes, where, once cleaved, the ends of the RNA are circularized by ligation through the endogenous RNA ligase RtcB. This platform was used to develop RNA devices that detect intracellular SAM concentrations and inhibit the cell-signalling protein NF- κ B¹¹⁸.

circRNAs can also be engineered to act as non-natural miRNA sponges¹¹⁹. One recent study reported the engineering of a synthetic circRNA with multiple binding sites for miR-122 to act as a miR-122 sponge¹²⁰ (FIG. 4Bb). miR-122 protects the 5' end of the hepatitis C virus (HCV) genome from degradation and enhances viral replication and translation. The engineered circRNAs were transcribed and circularized *in vitro*, and subsequently transfected into human hepatoma cell lines Huh-7 and Huh-7.5, where they sequestered miR-122 and resulted in lower HCV infection^{120,121}. circRNAs have also been developed as sponges for proteins¹²². Researchers engineered and integrated a construct that would become a circRNA with 100 CA dinucleotides when transcribed in HEK293 cells. These CA repeats are a known binding site for heterogeneous nuclear ribonuclear protein L (hnRNPL), a regulator of alternative splicing. When the circRNA was expressed, a shift in alternative splicing was observed across the genome. These early studies show that circRNAs can be used for long-lasting protein production in mammalian cells and function as sponges for other RNAs and RNA-binding proteins.

Despite these recent advances, circRNAs remain underexplored in the field largely due to the difficulty in detecting and measuring the concentration of circRNAs distinct from their cognate linear isoforms¹²³. As a result, we still do not fully understand the cellular

role circRNAs play and, thus, what unintentional effects overexpression of engineered circRNAs may have on cells. Advances in methods to detect and quantify circRNAs in cells are critical to supporting the development of this RNA platform into a broader engineering tool for the field.

RNA scaffolds serve as modular substrate for programming spatial organization. Beyond these examples of incorporating new RNA biology, scientists have utilized RNA to achieve genetically encodable, biological elements that do not have known RNA counterparts in nature. One way RNA can be repurposed is as a scaffold for various cellular processes¹²⁴. For instance, RNA scaffolds have been engineered into cells to co-localize enzymes in a biosynthetic pathway, increasing the local concentration of the metabolites and enzymes, and thus the rate at which reactants can be converted into pathway products. In one example, researchers working with *E. coli* designed a set of RNA sequences encoding aptamers in a 2D scaffold and then co-expressed four enzymes involved in succinate production that were fused to the corresponding aptamer-binding protein domains¹²⁵ (FIG. 4Ca). The RNA-scaffolded pathway exhibited an 88% increase in succinate production when compared with a control strain.

In another example, scientists replaced a protein-based scaffold in the caspase pathway for apoptosis with an RNA-based scaffold¹²⁶ (FIG. 4Cb). Caspase 8 normally requires a protein scaffold for proximity oligomerization to occur, which triggers the cell-death cascade. Researchers fused Caspase 8 to L7Ae, an RNA-binding protein, and designed an RNA scaffold harbouring L7Ae binding sequences. When the fusion protein and RNA scaffold were present in cells, the caspase pathway was triggered, leading to programmed apoptosis. The authors built a targeted RNA device that induced expression of the L7Ae–Caspase 8 fusion upon binding of specific miRNAs, resulting in cell death. The resulting RNA device enabled selective control of cell death in HeLa cells, achieving apoptosis rates more than double those of background levels (up to 70%) with the full L7Ae–Caspase 8 device.

Strategies using engineered RNA as a platform to assemble and organize molecules inside cells are currently limited in the size and diversity of known scaffolds. Development of future RNA scaffolds may require the design of basic RNA building blocks that could be combined in a modular fashion to form diverse and programmable structures that can control orientation and organization inside cells. Diverse RNA elements could ultimately be integrated throughout the resulting scaffold to achieve dynamic control over spatial organization via conformational changes.

Conclusions and perspective

RNA science has flourished in the last decade. Two mRNA vaccines against SARS-CoV-2 were designed, manufactured and distributed to hundreds of millions of people in the span of 18 months^{127–129}. This achievement has highlighted the promise of engineered RNA and has led to substantial public and private-sector

investments in both basic and applied research and development^{130–133}. Fulfilling the potential of this field will require partnerships between basic and applied researchers, organizations, commercial entities and funding bodies.

RNA engineering has lagged behind protein engineering, despite RNA's simpler component parts and robust secondary-structure modelling. However, recent progress in RNA engineering tool development provides optimism as similar advances accelerated the field of protein engineering. The goal of RNA device engineering must be to, at the very least, match nature's level of proficiency with RNA polymers. To achieve this, the field should take inspiration from the development of the protein design field. Protein engineers have access to large, well-annotated, public libraries of protein data. These shared resources have allowed for the development of powerful computational tools for de novo protein design^{134–137}. Building out similar shared resources for RNA will require coordination within the field. The utility of medium-throughput RNA structural determination has been spurred on by recent advances in cryogenic electron microscopy, nuclear magnetic resonance and chemical mapping, as well as the application

of new statistical techniques for RNA tertiary structure prediction^{138–142}. Partnerships that focus on the further development, application and scaling of these tools should be incentivized.

Inspired by coordinated efforts in the protein and enzymology fields, RNA foundries should be established to focus on scaling high-throughput methods to generate open-source libraries of standard, well-characterized RNA components that can be used widely by the field in support of new device generation^{23,81,88}. Scaling such efforts will ensure a critical open resource to advance the broader adoption of RNA devices in research, commercial and clinical settings. Larger consortiums should be established to focus on tool development to advance RNA biology and engineering, including work to improve in vitro transcription, RNA quantification, in vitro and in vivo RNA modifications, targeting of RNA by small-molecule drugs and the delivery and immunogenicity of RNA therapeutics^{69,123,143–146}. As momentum in the field continues to grow, engineered RNA devices will fulfil their potential as precision engineered systems.

Published online 4 January 2022

- Nshogozabazizi, J. C., Aubrey, K. L., Ross, J. A. & Thakor, N. Applications and limitations of regulatory RNA elements in synthetic biology and biotechnology. *J. Appl. Microbiol.* **127**, 968–984 (2019).
- Kim, J. & Franco, E. RNA nanotechnology in synthetic biology. *Curr. Opin. Biotechnol.* **63**, 135–141 (2020).
- Schmidt, C. M. & Smolke, C. D. RNA switches for synthetic biology. *Cold Spring Harb. Perspect. Biol.* **11**, 135–141 (2019).
- Park, S. V. et al. Catalytic RNA, ribozyme, and its applications in synthetic biology. *Biotechnol. Adv.* **37**, 107452 (2019).
- Win, M. N., Liang, J. C. & Smolke, C. D. Frameworks for programming biological function through RNA parts and devices. *Chem. Biol.* **16**, 298–310 (2009).
- Liang, J. C., Bloom, R. J. & Smolke, C. D. Engineering biological systems with synthetic RNA molecules. *Mol. Cell* **43**, 915–926 (2011).
- Nahvi, A. et al. Genetic control by a metabolite binding mRNA. *Chem. Biol.* **9**, 1043–1049 (2002).
- Winkler, W. C., Cohen-Chalamish, S. & Breaker, R. R. An mRNA structure that controls gene expression by binding FMN. *Proc. Natl Acad. Sci. USA* **99**, 15908–15913 (2002).
- Sudarsan, N., Barrick, J. E. & Breaker, R. R. Metabolite-binding RNA domains are present in the genes of eukaryotes. *RNA* **9**, 644–647 (2003).
- Isaacs, F. J. et al. Engineered riboregulators enable post-transcriptional control of gene expression. *Nat. Biotechnol.* **22**, 841–847 (2004).
- Suess, B. & Weigand, J. E. Engineered riboswitches: overview, problems and trends. *RNA Biol.* **5**, 24–29 (2008).
- McKeague, M., Wong, R. S. & Smolke, C. D. Opportunities in the design and application of RNA for gene expression control. *Nucleic Acids Res.* **44**, 2987–2999 (2016).
- Westbrook, A. M. & Lucks, J. B. Achieving large dynamic range control of gene expression with a compact RNA transcription–translation regulator. *Nucleic Acids Res.* **45**, 5614–5624 (2017).
- Kim, J. et al. De novo-designed translation-repressing riboregulators for multi-input cellular logic. *Nat. Chem. Biol.* **15**, 1173–1182 (2019).
- Rauch, S., Jones, K. A. & Dickinson, B. C. Small molecule-inducible RNA-targeting systems for temporal control of RNA regulation. *ACS Cent. Sci.* **6**, 1987–1996 (2020).
- Chappell, J., Westbrook, A., Verosloff, M. & Lucks, J. B. Computational design of small transcription activating RNAs for versatile and dynamic gene regulation. *Nat. Commun.* **8**, 1051 (2017).
- Anzalone, A. V., Lin, A. J., Zairis, S., Rabadan, R. & Cornish, V. W. Reprogramming eukaryotic translation with ligand-responsive synthetic RNA switches. *Nat. Methods* **13**, 453–458 (2016).
- Spöring, M., Finke, M. & Hartig, J. S. Aptamers in RNA-based switches of gene expression. *Curr. Opin. Biotechnol.* **63**, 34–40 (2020).
- Kawasaki, S., Ono, H., Hirotsawa, M. & Saito, H. RNA and protein-based nanodevices for mammalian post-transcriptional circuits. *Curr. Opin. Biotechnol.* **63**, 99–110 (2020).
- Endy, D. Foundations for engineering biology. *Nature* **438**, 449–453 (2005).
- Barrick, J. E. & Breaker, R. R. The distributions, mechanisms, and structures of metabolite-binding riboswitches. *Genome Biol.* **8**, R239 (2007).
- Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. *Nature* **346**, 818–822 (1990).
- Lauridsen, L. H., Doessing, H. B., Long, K. S. & Nielsen, A. T. in *Synthetic Metabolic Pathways: Methods and Protocols* (eds. Jensen, M. K. & Keasling, J. D.) 291–306 (Springer, 2018).
- Baird, G. S. Where are all the aptamers? *Am. J. Clin. Pathol.* **134**, 529–531 (2010).
- Dunn, M. R., Jimenez, R. M. & Chaput, J. C. Analysis of aptamer discovery and technology. *Nat. Rev. Chem.* **1**, 0076 (2017).
- McKeague, M. & DeRosa, M. C. Challenges and opportunities for small molecule aptamer development. *J. Nucleic Acids* **2012**, 1–20 (2012).
- McKeague, M. et al. Analysis of in vitro aptamer selection parameters. *J. Mol. Evol.* **81**, 150–161 (2015).
- Valencia-Sanchez, M. A., Liu, J., Hannon, G. J. & Parker, R. Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes Dev.* **20**, 515–524 (2006).
- Bloom, R. J., Winkler, S. M. & Smolke, C. D. Synthetic feedback control using an RNAi-based gene-regulatory device. *J. Biol. Eng.* **9**, 5 (2015).
- Lucks, J. B., Qi, L., Mutalik, V. K., Wang, D. & Arkin, A. P. Versatile RNA-sensing transcriptional regulators for engineering genetic networks. *Proc. Natl Acad. Sci. USA* **108**, 8617–8622 (2011).
- Ausländer, S. & Fussenegger, M. Synthetic RNA-based switches for mammalian gene expression control. *Curr. Opin. Biotechnol.* **48**, 54–60 (2017).
- Chappell, J. et al. The centrality of RNA for engineering gene expression. *Biotechnol. J.* **8**, 1379–1395 (2013).
- Till, P., Toepel, J., Bühler, B., Mach, R. L. & Mach-Aigner, A. R. Regulatory systems for gene expression control in cyanobacteria. *Appl. Microbiol. Biotechnol.* **104**, 1977–1991 (2020).
- Bayer, T. S. & Smolke, C. D. Programmable ligand-controlled riboregulators of eukaryotic gene expression. *Nat. Biotechnol.* **23**, 337–343 (2005).
- Kawasaki, S., Fujita, Y., Nagaike, T., Tomita, K. & Saito, H. Synthetic mRNA devices that detect endogenous proteins and distinguish mammalian cells. *Nucleic Acids Res.* **45**, e117–e117 (2017).
- Paige, J. S., Nguyen-Duc, T., Song, W. & Jaffrey, S. R. Fluorescence imaging of cellular metabolites with RNA. *Science* **335**, 1194–1194 (2012).
- Jepsen, M. D. E. et al. Development of a genetically encodable FRET system using fluorescent RNA aptamers. *Nat. Commun.* **9**, 18 (2018).
- Wurmthaler, L. A., Sack, M., Gense, K., Hartig, J. S. & Gerdinger, M. A tetracycline-dependent ribozyme switch allows conditional induction of gene expression in *Caenorhabditis elegans*. *Nat. Commun.* **10**, 491 (2019).
- Gu, H., Furukawa, K. & Breaker, R. R. Engineered allosteric ribozymes that sense the bacterial second messenger cyclic diguanosyl 5'-monophosphate. *Anal. Chem.* **84**, 4935–4941 (2012).
- Niu, T. et al. Engineering a glucosamine-6-phosphate responsive glmS ribozyme switch enables dynamic control of metabolic flux in *Bacillus subtilis* for overproduction of N-acetylglucosamine. *ACS Synth. Biol.* **7**, 2423–2435 (2018).
- Stern, R. C. & Stern, R. M. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer J.* **11**, 1–11 (2021).
- Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. *N. Engl. J. Med.* **365**, 1673–1683 (2011).
- Chen, Y. Y., Jensen, M. C. & Smolke, C. D. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. *Proc. Natl Acad. Sci. USA* **107**, 8531–8536 (2010).
- Wong, R. S., Chen, Y. Y. & Smolke, C. D. Regulation of T cell proliferation with drug-responsive microRNA switches. *Nucleic Acids Res.* **46**, 1541–1552 (2018).
- Liu, Y. et al. Directing cellular information flow via CRISPR signal conductors. *Nat. Methods* **13**, 938–944 (2016).
- Liu, Y. et al. Engineering cell signaling using tunable CRISPR–Cpf1-based transcription factors. *Nat. Commun.* **8**, 2095 (2017).
- Tang, W., Hu, J. H. & Liu, D. R. Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation. *Nat. Commun.* **8**, 15939 (2017).

48. Hoffmann, M. D. et al. Cell-specific CRISPR–Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins. *Nucleic Acids Res.* **47**, e75 (2019).
49. Hirose, M. et al. Cell-type-specific genome editing with a microRNA-responsive CRISPR–Cas9 switch. *Nucleic Acids Res.* **45**, e118 (2017).
50. Hirose, M., Fujita, Y. & Saito, H. Cell-type-specific CRISPR activation with microRNA-responsive AcrIIA4 switch. *ACS Synth. Biol.* **8**, 1575–1582 (2019).
51. Lee, J. et al. Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins. *RNA* **25**, 1421–1431 (2019).
52. Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A. & Liu, D. R. Small molecule-triggered Cas9 protein with improved genome-editing specificity. *Nat. Chem. Biol.* **11**, 316–318 (2015).
53. Robbins, P. D., Tahara, H. & Ghivizzani, S. C. Viral vectors for gene therapy. *Trends Biotechnol.* **16**, 35–40 (1998).
54. Strobel, B. et al. Riboswitch-mediated attenuation of transgene cytotoxicity increases adeno-associated virus vector yields in HEK-293 cells. *Mol. Ther.* **23**, 1582–1591 (2015).
55. Takahashi, K. & Yokobayashi, Y. Reversible gene regulation in mammalian cells using riboswitch-engineered vesicular stomatitis virus vector. *ACS Synth. Biol.* **8**, 1976–1982 (2019).
56. Reid, C. A., Nettekheim, E. R., Connor, T. B. & Lipinski, D. M. Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. *Sci. Rep.* **8**, 11763 (2018).
57. Strobel, B. et al. A small-molecule-responsive riboswitch enables conditional induction of viral vector-mediated gene expression in mice. *ACS Synth. Biol.* **9**, 1292–1305 (2020).
58. Han, S. R. et al. Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation. *Mol. Ther. Nucleic Acids* **23**, 154–168 (2021).
59. Wang, H. et al. Characterization of a bifunctional synthetic RNA aptamer and a truncated form for ability to inhibit growth of non-small cell lung cancer. *Sci. Rep.* **9**, 18836 (2019).
60. Worgall, S., Wolff, G., Falck-Pedersen, E. & Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. *Hum. Gene Ther.* **8**, 37–44 (1997).
61. Uehata, T. & Takeuchi, O. RNA recognition and immunity-innate immune sensing and its posttranscriptional regulation mechanisms. *Cells* **9**, E1701 (2020).
62. Ireton, R. C., Wilkins, C. & Gale, M. RNA PAMPs as molecular tools for evaluating RIG-I function in innate immunity. *Methods Mol. Biol.* **1656**, 119–129 (2017).
63. Kell, A. M. & Gale, M. RIG-I in RNA virus recognition. *Virology* **479–480**, 110–121 (2015).
64. Wu, M. Z., Asahara, H., Tzertzinis, G. & Roy, B. Synthesis of low immunogenicity RNA with high-temperature in vitro transcription. *RNA* **26**, 345–360 (2020).
65. Andries, O. et al. N¹-Methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. *J. Control. Rel.* **217**, 337–344 (2015).
66. Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol. Ther.* **16**, 1833–1840 (2008).
67. Wesselhoeft, R. A. et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. *Mol. Cell* **74**, 508–520.e4 (2019).
68. Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. *Curr. Opin. Immunol.* **65**, 14–20 (2020).
69. Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C. & Thakur, A. Opportunities and challenges in the delivery of mRNA-based vaccines. *Pharmaceutics* **12**, E102 (2020).
70. Dua, P., Kim, S. & Lee, D. Nucleic acid aptamers targeting cell-surface proteins. *Methods* **54**, 215–225 (2011).
71. Narberhaus, F., Waldmingerhaus, T. & Chowdhury, S. RNA thermometers. *FEMS Microbiol. Rev.* **30**, 3–16 (2006).
72. Neupert, J., Karcher, D. & Bock, R. Design of simple synthetic RNA thermometers for temperature-controlled gene expression in *Escherichia coli*. *Nucleic Acids Res.* **36**, e124–e124 (2008).
73. Lotz, T. S. et al. A light-responsive RNA aptamer for an azobenzene derivative. *Nucleic Acids Res.* **47**, 2029–2040 (2019).
74. Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS ONE* **5**, e15004 (2010).
75. Darmostuk, M., Rimpelova, S., Gbelcova, H. & Ruml, T. Current approaches in SELEX: an update to aptamer selection technology. *Biotechnol. Adv.* **33**, 1141–1161 (2015).
76. Wayment-Steele, H., Wu, M., Gotrik, M. & Das, R. in *Methods in Enzymology* Vol. 623 Ch. 18 (ed. Hargrove, A. E.) 417–450 (Academic, 2019).
77. Davis, J. H. & Szostak, J. W. Isolation of high-affinity GTP aptamers from partially structured RNA libraries. *Proc. Natl. Acad. Sci. USA* **99**, 11616–11621 (2002).
78. Kohlberger, M. & Gadermaier, G. SELEX: critical factors and optimization strategies for successful aptamer selection. *Biotechnol. Appl. Biochem.* <https://doi.org/10.1002/bab.2244> (2021).
79. Komarova, N. & Kuznetsov, A. Inside the black box: what makes SELEX better? *Molecules* **24**, E3598 (2019).
80. Ricci, F., Vallée-Bélisle, A., Simon, A. J., Porchetta, A. & Plaxco, K. W. Using nature's "tricks" to rationally tune the binding properties of biomolecular receptors. *Acc. Chem. Res.* **49**, 1884–1892 (2016).
81. Townshend, B., Xiang, J. S., Manzanarez, G., Hayden, E. J. & Smolke, C. D. A multiplexed, automated evolution pipeline enables scalable discovery and characterization of biosensors. *Nat. Commun.* **12**, 1437 (2021).
82. Hasegawa, H., Savory, N., Abe, K. & Ikebukuro, K. Methods for improving aptamer binding affinity. *Molecules* **21**, 421 (2016).
83. Kalra, P., Dhiman, A., Cho, W. C., Bruno, J. G. & Sharma, T. K. Simple methods and rational design for enhancing aptamer sensitivity and specificity. *Front. Mol. Biosci.* **5**, 41 (2018).
84. Stoltenburg, R., Nikolaus, N. & Strehlitz, B. Capture-SELEX: selection of DNA aptamers for aminoglycoside antibiotics. *J. Anal. Methods Chem.* **2012**, 1–14 (2012).
85. Boussebayle, A., Groher, F. & Suess, B. RNA-based Capture-SELEX for the selection of small molecule-binding aptamers. *Methods* **161**, 10–15 (2019).
86. Koizumi, M., Soukup, G. A., Kerr, J. N. & Breaker, R. R. Allosteric selection of ribozymes that respond to the second messengers cGMP and cAMP. *Nat. Struct. Biol.* **6**, 1062–1071 (1999).
87. Xiang, J. S. et al. Massively parallel RNA device engineering in mammalian cells with RNA-seq. *Nat. Commun.* **10**, 4327 (2019).
88. Strobel, B. et al. High-throughput identification of synthetic riboswitches by barcode-free amplicon-sequencing in human cells. *Nat. Commun.* **11**, 1–12 (2020).
89. Townshend, B., Kennedy, A. B., Xiang, J. S. & Smolke, C. D. High-throughput cellular RNA device engineering. *Nat. Methods* **12**, 989–994 (2015).
90. Nomura, Y., Chien, H.-C. & Yokobayashi, Y. Direct screening for ribozyme activity in mammalian cells. *Chem. Commun.* **53**, 12540–12543 (2017).
91. Gotrik, M. et al. Direct selection of fluorescence-enhancing RNA aptamers. *J. Am. Chem. Soc.* **140**, 3583–3591 (2018).
92. Zhao, B. S., Roundtree, I. A. & He, C. Post-transcriptional gene regulation by mRNA modifications. *Nat. Rev. Mol. Cell Biol.* **18**, 31–42 (2017).
93. Holley, R. W., Everett, G. A., Madison, J. T. & Zamir, A. Nucleotide sequences in the yeast alanine transfer ribonucleic acid. *J. Biol. Chem.* **240**, 2122–2128 (1965).
94. Pereira, M. et al. Impact of tRNA modifications and tRNA-modifying enzymes on proteostasis and human disease. *Int. J. Mol. Sci.* **19**, E3738 (2018).
95. Dominissini, D. et al. Topology of the human and mouse m⁶A RNA methylomes revealed by m⁶A-seq. *Nature* **485**, 201–206 (2012).
96. Meyer, K. D. et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* **149**, 1635–1646 (2012).
97. Jaffrey, S. R. & Kharas, M. G. Emerging links between m⁶A and misregulated mRNA methylation in cancer. *Genome Med.* **9**, 2 (2017).
98. Liu, J. et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA N⁶-adenosine methylation. *Nat. Chem. Biol.* **10**, 93–95 (2014).
99. Wilson, C., Chen, P. J., Miao, Z. & Liu, D. R. Programmable m⁶A modification of cellular RNAs with a Cas13-directed methyltransferase. *Nat. Biotechnol.* **38**, 1431–1440 (2020).
100. Xiao, W. et al. Nuclear m⁶A reader YTHDC1 regulates mRNA splicing. *Mol. Cell* **61**, 507–519 (2016).
101. Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat. Rev. Genet.* **19**, 770–788 (2018).
102. Marina, R. J., Brannan, K. W., Dong, K. D., Yee, B. A. & Yeo, G. W. Evaluation of engineered CRISPR-cas-mediated systems for site-specific RNA editing. *Cell Rep.* **33**, 108350 (2020).
103. Qu, L. et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. *Nat. Biotechnol.* **37**, 1059–1069 (2019).
104. Cox, D. B. T. et al. RNA editing with CRISPR–Cas13. *Science* **358**, 1019–1027 (2017).
105. Rauch, S. et al. Programmable RNA-guided RNA effector proteins built from human parts. *Cell* **178**, 122–134.e12 (2019).
106. Abudayeh, O. O. et al. A cytosine deaminase for programmable single-base RNA editing. *Science* **365**, 382–386 (2019).
107. Salzman, J. Circular RNA expression: its potential regulation and function. *Trends Genet.* **32**, 309–316 (2016).
108. Lasda, E. & Parker, R. Circular RNAs: diversity of form and function. *RNA* **20**, 1829–1842 (2014).
109. Akhter, R. Circular RNA and Alzheimer's disease. *Adv. Exp. Med. Biol.* **1087**, 239–243 (2018).
110. Altesha, M.-A., Ni, T., Khan, A., Liu, K. & Zheng, X. Circular RNA in cardiovascular disease. *J. Cell Physiol.* **234**, 5588–5600 (2019).
111. Han, B., Chao, J. & Yao, H. Circular RNA and its mechanisms in disease: from the bench to the clinic. *Pharmacol. Ther.* **187**, 31–44 (2018).
112. Prats, A.-C. et al. Circular RNA, the key for translation. *Int. J. Mol. Sci.* **21**, 8591 (2020).
113. Legnini, I. et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. *Mol. Cell* **66**, 22–37.e9 (2017).
114. Pamudurti, N. R. et al. Translation of circRNAs. *Mol. Cell* **66**, 9–21.e7 (2017).
115. Litke, J. L. & Jaffrey, S. R. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. *Nat. Biotechnol.* **37**, 667–675 (2019).
116. Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. *Nat. Commun.* **9**, 2629 (2018).
117. Meganck, R. M. et al. Engineering highly efficient backsplicing and translation of synthetic circRNAs. *Mol. Ther. Nucleic Acids* **23**, 821–834 (2021).
118. Paige, J. S., Wu, K. Y. & Jaffrey, S. R. RNA mimics of green fluorescent protein. *Science* **333**, 642–646 (2011).
119. Rossbach, O. Artificial circular RNA sponges targeting microRNAs as a novel tool in molecular biology. *Mol. Ther. Nucleic Acids* **17**, 452–454 (2019).
120. Jost, I. et al. Functional sequestration of microRNA-122 from hepatitis C virus by circular RNA sponges. *RNA Biol.* **15**, 1032–1039 (2018).
121. Blight, K. J., McKeating, J. A. & Rice, C. M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *J. Virol.* **76**, 13001–13014 (2002).
122. Schreiner, S., Dido, A., Hung, L.-H. & Bindereif, A. Design and application of circular RNAs with protein-sponge function. *Nucleic Acids Res.* **48**, 12326–12335 (2020).
123. Li, X., Yang, L. & Chen, L.-L. The biogenesis, functions, and challenges of circular RNAs. *Mol. Cell* **71**, 428–442 (2018).
124. Delebecq, C. J., Lindner, A. B., Silver, P. A. & Aldaye, F. A. Organization of intracellular reactions with rationally designed RNA assemblies. *Science* **333**, 470–474 (2011).
125. Sachdeva, G., Garg, A., Godding, D., Way, J. C. & Silver, P. A. In vivo co-localization of enzymes on RNA scaffolds increases metabolic production in a geometrically dependent manner. *Nucleic Acids Res.* **42**, 9493–9503 (2014).
126. Shibata, T. et al. Protein-driven RNA nanostructured devices that function in vitro and control mammalian cell fate. *Nat. Commun.* **8**, 540 (2017).
127. WHO. WHO coronavirus (COVID-19) dashboard with vaccination data. *World Health Organization* <https://covid19.who.int/info> (2020).
128. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).

129. Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature* **586**, 567–571 (2020).
130. Slaoui, M. & Hepburn, M. Developing safe and effective covid vaccines — Operation Warp Speed's strategy and approach. *N. Engl. J. Med.* **383**, 1701–1703 (2020).
131. Bell, J. Moderna founder's next big play in RNA raises \$440M. *BioPharma Dive* <https://www.biopharmadive.com/news/laronde-endless-rna-series-b-flagship-moderna/605740/> (2021).
132. Bell, J. Venture capital pours more money into RNA medicines with the launch of Replicate. *BioPharma Dive* <https://www.biopharmadive.com/news/replicate-launch-rna-ehlers-apple-tree/606210/> (2021).
133. Al Idrus, A. Shape builds out RNA editing tech with a major \$112M funding boost. *FierceBiotech* <https://www.fiercebiotech.com/biotech/shape-therapeutics-reels-112m-to-spur-rna-editing-tech> (2021).
134. Baek, M. et al. Accurate prediction of protein structures and interactions using a three-track neural network. *Science* **373**, 871–876 (2021).
135. Senior, A. W. et al. Improved protein structure prediction using potentials from deep learning. *Nature* **577**, 706–710 (2020).
136. Kuhlman, B. & Bradley, P. Advances in protein structure prediction and design. *Nat. Rev. Mol. Cell Biol.* **20**, 681–697 (2019).
137. Langan, R. A. et al. De novo design of bioactive protein switches. *Nature* **572**, 205–210 (2019).
138. Zhang, K. et al. Cryo-EM structure of a 40 kDa SAM-IV riboswitch RNA at 3.7 Å resolution. *Nat. Commun.* **10**, 5511 (2019).
139. Mustoe, A. M., Lama, N. N., Irving, P. S., Olson, S. W. & Weeks, K. M. RNA base-pairing complexity in living cells visualized by correlated chemical probing. *Proc. Natl Acad. Sci. USA* **116**, 24574–24582 (2019).
140. Yesselman, J. D. et al. Computational design of three-dimensional RNA structure and function. *Nat. Nanotechnol.* **14**, 866–873 (2019).
141. Watkins, A. M., Rangan, R. & Das, R. FARFAR2: improved de novo Rosetta prediction of complex global RNA folds. *Structure* **28**, 963–976.e6 (2020).
142. Townshend, R. J. L. et al. Geometric deep learning of RNA structure. *Science* **373**, 1047–1051 (2021).
143. Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. *Vaccine* **39**, 2190–2200 (2021).
144. Shi, H. et al. Bias in RNA-seq library preparation: current challenges and solutions. *Biomed. Res. Int.* **2021**, 6647597 (2021).
145. Yu, A.-M., Choi, Y. H. & Tu, M.-J. RNA drugs and RNA targets for small molecules: principles, progress, and challenges. *Pharmacol. Rev.* **72**, 862–898 (2020).
146. Schlick, T. & Pyle, A. M. Opportunities and challenges in RNA structural modeling and design. *Biophysical J.* **113**, 225–234 (2017).
147. Potter, K., Cremona, N. & Wise, J. A. in *Encyclopedia of Biological Chemistry* 2nd edn (eds Lennarz, W. J. & Lane, M. D.) 59–64 (Academic, 2013).
148. Wilkinson, M. E., Charenton, C. & Nagai, K. RNA splicing by the spliceosome. *Annu. Rev. Biochem.* **89**, 359–388 (2020).
149. Chen, L.-L. The biogenesis and emerging roles of circular RNAs. *Nat. Rev. Mol. Cell Biol.* **17**, 205–211 (2016).
150. Zhang, X. et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. *Mol. Cancer* **18**, 20 (2019).
151. Cesana, M. et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell* **147**, 358–369 (2011).
152. Merkle, T. et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. *Nat. Biotechnol.* **37**, 133–138 (2019).

Acknowledgements

The authors thank J. Payne, P. Srinivasan and B. Townshend for valuable feedback in the preparation of this Review. This work was supported by the National Institutes of Health (NIH) (grant to C.D.S.), National Science Foundation (NSF) (graduate fellowships to P.B.D. and M.K.) and Howard Hughes Medical Institute (HHMI) (Gilliam graduate fellowship to M.K.). C.D.S. is a Chan Zuckerberg Biohub investigator.

Author contributions

The authors contributed equally to all aspects of the article.

Competing interests

The authors declare no competing interests.

Peer review information

Nature Reviews Genetics thanks James M. Carothers, James J. Collins and Hirohide Saito for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2022